Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) EBIT (2016 - 2025)

Fennec Pharmaceuticals filings provide 15 years of EBIT readings, the most recent being $2.2 million for Q4 2025.

  • On a quarterly basis, EBIT rose 336.94% to $2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.5 million, a 159.03% decrease, with the full-year FY2025 number at -$1.5 million, down 159.0% from a year prior.
  • EBIT hit $2.2 million in Q4 2025 for Fennec Pharmaceuticals, up from -$189000.0 in the prior quarter.
  • In the past five years, EBIT ranged from a high of $13.7 million in Q1 2024 to a low of -$7.9 million in Q3 2022.
  • Median EBIT over the past 5 years was -$3.9 million (2021), compared with a mean of -$2.5 million.
  • The widest YoY moves for EBIT: up 360.78% in 2024, down 411.5% in 2024.
  • Fennec Pharmaceuticals' EBIT stood at -$4.2 million in 2021, then tumbled by 47.02% to -$6.1 million in 2022, then skyrocketed by 70.37% to -$1.8 million in 2023, then surged by 48.62% to -$934000.0 in 2024, then surged by 336.94% to $2.2 million in 2025.
  • The last three reported values for EBIT were $2.2 million (Q4 2025), -$189000.0 (Q3 2025), and -$2.7 million (Q2 2025) per Business Quant data.